Odiparcil

Odiparcil is a β-D-thioxyloside derivative and driver of circulating glycosaminoglycan (GAG) synthesis.^1,2 It increases the secretion of total sulfated GAGs in bovine aortic endothelial (BAE) cells when used at a concentration of 10 µM.¹ Odiparcil (10 µM) reduces intracellular chondroitin sulfate levels in primary skin fibroblasts isolated from patients with mucopolysaccharidosis type VI (MPS VI), an inborn error of metabolism characterized by a deficiency in the degradation of specific GAGs. Dietary administration of odiparcil (4.5 g/kg of chow) increases urinary excretion of sulfated GAGs and decreases hepatic and renal accumulation of sulfated GAGs in a mouse model of MPS VI induced by a homozygous gene mutation in the Arsb gene, which encodes the enzyme arylsulfatase B. Odiparcil reduces thrombus weight in a rat model of thrombosis (ED₅₀ = 3.2 mg/kg).²

WARNING This product is not for human or veterinary use.

1. Entchev, E., Jantzen, I., Masson, P., et al. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. PLoS One 15(5), e0233032 (2020).

2. Toomey, J.R., Abboud, M.A., Valocik, R.E., et al. A comparison of the β-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J. Thromb. Haemost. 4(9), 1989-1996 (2006).